key: cord-0311842-j5frnbwo authors: O'Leary, M. F.; Jackman, S. R.; Sabou, V. R.; Campbell, M. I.; Tang, J. C. Y.; Dutton, J.; Bowtell, J. L. title: Shatavari Supplementation in Postmenopausal Women Improves Handgrip Strength and Increases Vastus Lateralis Myosin Regulatory Light Chain Phosphorylation But Does Not Alter Markers of Bone Turnover: A Randomised Controlled Trial. date: 2021-09-20 journal: nan DOI: 10.1101/2021.09.16.21263687 sha: 780c13711aa7cb9bef87355d60c8288bd39eb0e5 doc_id: 311842 cord_uid: j5frnbwo Background: Shatavari has long been used as an Ayurvedic herb for women's health, but empirical evidence for its effectiveness has been lacking. Shatavari contains phytoestrogenic compounds that bind to the estradiol receptor, and may therefore benefit postmenopausal women since postmenopausal estradiol deficiency contributes to sarcopenia and osteoporosis. Methods: In a randomised double-blind trial, 20 postmenopausal women (68.5 {+/-} 6 y) ingested either placebo (N=10) or shatavari (N=10; 1000 mg/d, equivalent to 26,500 mg/d fresh weight shatavari) for 6 weeks. Handgrip and knee extensor strength were measured at baseline and at 6 weeks. Vastus lateralis (VL) biopsy samples were obtained. Data are presented and analysed (t test/Mann Whitney U) as difference scores (Week 6 - baseline, median {+/-} interquartile range). Results: Handgrip, (but not knee extensor) strength was improved by shatavari supplementation (shatavari +0.7 {+/-} 1.1 kg, placebo -0.4 {+/-} 1.3 kg; p=0.04). Myosin regulatory light chain phosphorylation, a known marker of improved myosin contractile function, was increased in VL following shatavari supplementation (immunoblotting; placebo -0.08 {+/-} 0.5 a.u. shatavari +0.3 {+/-} 1 arbitrary units (a.u.); p=0.03). Shatavari increased phosphorylation of Aktser473 (Aktser473 (placebo -0.6 {+/-} 0.6 a.u. shatavari +0.2 {+/-} 1.3 a.u; p=0.03) in VL. Shatavari supplementation did not alter plasma markers of bone turnover (P1NP, {beta}-CTX) and stimulation of human osteoblasts with pooled sera (N=8 per condition) from placebo and shatavari supplementation conditions did not alter cytokine or metabolic markers of osteoblast activity. Conclusions: Shatavari may improve muscle function and contractility via myosin conformational change and warrants further investigation of its utility in conserving musculoskeletal function in postmenopausal women. Trial Registration: Retrospectively registered at clinicaltrials.gov as NCT05025917 on 30/08/21. 4 shatavari increases serum prolactin concentration is unknown. Little is definitively known about 75 how herbal galactagogues act, beyond speculation that they have E2 like activity and rely upon 76 phytoestrogen interaction with Erα. [10, 11] . The potential for estrogen-like effects of shatavari supplementation has implications for both 78 muscle and bone health after the menopause. Observational data have long suggested that in 79 women, post-menopausal estrogenic deficits may promote the age-associated decline in muscle E2 withdrawal has a detrimental effect on myosin binding function and therefore muscle force 85 production; conversely E2 improves muscle force production, and may promote muscle protein 86 synthesis [14] [15] [16] . One study has shown that shatavari (500 mg·d −1 root extract; fresh weight 87 equivalent not stated) enhanced strength gains in young men following eight weeks of bench 88 press training [17] ; this was an observational study with no indication of possible mechanisms of 89 action. However, it does suggest that shatavari may be a beneficial ergogenic aid in supporting 90 resistance training-induced increases in muscle size and strength; no assessment of these 91 ergogenic effects has been made in older adults. The decreased E2 production that precipitates menopause is also associated with a decline in 93 bone mineral density, a phenomenon that increases the risk of bone fractures [18] . Elderly 94 individuals that experience a hip fracture have a 3-fold increase in their risk of all-cause mortality 95 [19] . HRT decreases the risk of osteoporosis and fractures [20] . Clinical trials that suggested 96 limited therapeutic benefit of HRT and an increased risk of harm (breast cancer, cardiovascular 97 disease) have recently been reassessed and HRT has once again been determined to have a 98 clinical benefit and an acceptable safety profile; despite this, uptake of HRT has declined [20] . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Given the phytoestrogen content of shatavari and evidence of its estrogen-like effects in vivo we 118 hypothesised that six weeks shatavari supplementation in postmenopausal women would induce 119 increases in in vivo molecular markers of skeletal muscle contractility and protein synthesis. We 120 further hypothesised that sera from shatavari supplemented participants would promote a positive 121 bone turnover phenotype in primary human osteoblasts in vitro. Secondarily in this initial six week 122 supplementation study, we measured HGS and knee extensor strength, hypothesising that 123 alterations in muscle contractility might be evident in this timeframe. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Participants sat in a standard chair rested their forearms on the armrest. The wrist was positioned 160 just over the end of the armrest, in a neutral position with the thumb facing upwards. Each hand 161 was tested three times and the tested hand was alternated. The best score for either hand was Femoral head donors were postmenopausal women (73 ± 9.9 y BMI 29.6 ± 8.6) undergoing hip 220 replacement. Exclusion criteria were: last menstrual period < 12 months previously; use of 221 estrogenic or progestogenic hormone replacement therapy via oral, transdermal, subcutaneous 222 implant routes in previous five years, diagnosis of osteoporosis or osteopenia, taking any 223 medication for the prevention of osteoporosis, including bisphosphonates and non- . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint the magnitude of such an effect with shatavari supplementation might be expected to be 286 considerably less than that seen with HRT treatment. Thus, we calculated based on a standard 287 deviation of 40% from the mean (unpublished data, calculated SD from n = 9 myogenin western 288 blot quantifications from elderly men) that we would be able to detect a 1.6-fold change in 289 myogenin expression with 11 participants per group. We will therefore recruited 12 participants 290 per group to allow for dropouts. Given the evidence from the literature of an effect of HRT on 291 myogenin expression, and the lack of evidence regarding the effects of shatavari in skeletal 292 muscle, this measure was originally designated as our primary outcome measure. However, the 293 shutdown of our lab facility due to the Covid-19 pandemic lead to the loss of a large number of 294 consumables, including the degradation of many of our immunoblotting antibody stocks that 295 required extensive subsequent troubleshooting. Despite myogenin expression being the 296 designated primary outcome measure, we were forced to use our limited muscle sample stocks 297 to quantify outcomes that required less extensive troubleshooting. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Six weeks of shatavari supplementation improved HGS in this cohort (placebo -0.4 ± 1.3 kg, 315 shatavari +0.7 ± 1.1 kg; p = 0.04, Mann Whitney U, Figure 1A ). Knee extensor isometric (placebo 316 0 ± 7.8 N, shatavari -4.8 ± 6 N; p=0.14, t-test), concentric (placebo +4.9 ± 10.2 N, shatavari +0.96 317 ± 6.8 N; p = 0.33, t-test), and eccentric (placebo +2.9 ± 12.1 N, shatavari +5.1 ± 10.7 N; p = 0.67, 318 t-test) strength were not altered by supplement condition (Figure 1 B-C) . p=0.25, t-test), IL-6 (placebo +58.8 ± 284.9 pg/mL, shatavari +189.6 ± 344.5 pg/mL; p=0.39, Mann 347 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This is the first study to assess the effect of shatavari on skeletal muscle function in a cohort of 362 older adults and the first offer insights into the molecular changes that may underpin its functional 363 effects. To our knowledge, this is also the first study to assess the effect of shatavari . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Perhaps surprisingly in the context of the shatavari-induced changes in HGS, knee extensor 386 strength was not increased despite an increase in VL pMLC. Our subjective experience during 387 this study was that the learning effect of our familiarisation session for this older adult cohort was 388 not as effective as the same familiarisation protocol that we use regularly in younger cohorts. Indeed, there may be greater variability in reaching maximum voluntary activation in older age 390 and our 'best of three' approach to such tests [37] may need to be modified in such cohorts to 391 take the best value from a greater number of attempts [38] . Testing of HGS is an inherently more CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.16.21263687 doi: medRxiv preprint group was 2.9 ± 2.3 %; the CV for the best MVC value was 4.1 ± 4 %, although this did not reach 397 statistical significance (p = 0.46, t-test). Notably the CVs for concentric (8.2 ± 6.5 %) and eccentric 398 (6.6 ± 4.1 %) isokinetic measures of muscle strength were significantly larger than that for HGS 399 (p = 0.03, t-test for both). The lack of a forearm skeletal biopsy in the context of our HGS [40] . Our samples also often contained a high proportion of subcutaneous or 420 intramuscular adipose tissue, which accumulates in skeletal muscle with advancing age [41] . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We did not find any effect of shatavari supplemented sera on markers of primary human 451 osteoblast function, neither did we observe any changes in the osteoblast secretion of cytokines 452 that are known to alter osteoclast activity. In this six week supplementation study, these in vitro 453 assays of bone turnover activity were the bone outcomes of primary interest and considered the 454 most likely to be altered by supplement condition. However, we also quantified in vivo markers of 455 bone turnover (P1NP and β-CTX), with no effect of supplementation being observed. Given the 456 in vitro results that we describe, this is most likely due to a genuine lack of effect on shatavari on 457 bone turnover. However, despite best efforts in vitro models cannot perfectly reproduce human Here, we examined the potential benefits of shatavari supplementation for the musculoskeletal 465 system after the menopause and this initial study has signposted several novel effects and 466 promising avenues for further research in this area. Discussion of the limitations of our approach 467 and conclusions has been integrated into the main discussion. Specifically, we found that 468 shatavari appears to improve muscle function, potentially mediated by improvements in myosin 469 contractility and warrants further investigation of its utility in conserving musculoskeletal function 470 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.16.21263687 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.16.21263687 doi: medRxiv preprint Asparagus racemosus: a review on its phytochemical and 506 therapeutic potential Estrogenic Receptor-Functionalized Magnetite 511 Nanoparticles for Rapid Separation of Phytoestrogens in Plant Extracts Phytoestrogens: food or drug? Clinical Cases in Mineral and Age-related slowing of myosin actin cross-bridge kinetics is sex specific and predicts 602 decrements in whole skeletal muscle performance in humans Proteins modulation in human skeletal muscle in the early phase of adaptation to 606 hypobaric hypoxia Estradiol modulates 608 myosin regulatory light chain phosphorylation and contractility in skeletal muscle of female 609 mice Deletion of estrogen receptor α in skeletal muscle results in impaired contractility in 613 female mice Montmorency cherry 616 juice reduces muscle damage caused by intensive strength exercise Voluntary muscle activation varies with age and muscle 619 group Collection of Skeletal Muscle Biopsies from 622 the Superior Compartment of Human Musculus Tibialis Anterior for Mechanical Evaluation The challenges of muscle biopsy in a 625 community based geriatric population Adipose Tissue Quality in Aging: How Structural and Functional Aspects of Adipose Tissue 629 Impact Skeletal Muscle Quality Effect of Estrogen on Musculoskeletal Performance and 631 Injury Risk Growth Factor Axis and Resistance Exercise Muscle Adaptations Phytoestrogens: Dietary Intake Protective Mechanisms against Colorectal Neoproliferative Lesions Response of biochemical markers 640 of bone turnover to hormone replacement therapy: impact of biological variability We thank Dr Bea Knight, Ms Lidia Romanczuk and Mr John Charity for their assistance with this 497 research project. We thank Dr Vivien Rolfe, Marion Mackonochie and Simon Mills from Pukka 498 Herbs for useful discussions regarding the Ayurvedic uses of shatavari. This project was